South Korea Special Situations

Hong Sung-chun and 12 related parties filed a large-shareholding report for Emb Co.,Ltd. (278990.KS) disclosing an 83.7% stake consisting of 8,189,582 shares. The group identified the purpose of the holding as "management control influence" and controls voting rights of 80.22%. Related entity FineMtech increased its position by 38,427 shares through an off-market purchase on June 1, 2026, at KRW 6,340 per share. The disclosure follows South Korean rules triggered by a management-control declaration, which often precedes board or capital-structure changes. This filing serves as the local equivalent of a US 13D and signals consolidation or a potential squeeze-out rather than a hostile build given the controlling bloc already holds over 83% of the company.

Controlling shareholder Moon Yang Kwon and six related parties disclosed a 30.82% stake in Barunson Entertainment & Arts Corporation (035620.KQ), an increase from 28.17% in their prior 2024 filing. This update follows an April 2026 4-for-1 gratuitous capital reduction that decreased total issued shares from approximately 74.4 million to 18.6 million. Between May 22 and May 29, 2026, related party MI Company utilized a KRW 1.1 billion loan from Moon to acquire a 5.02% stake through market purchases. The group designated the holding purpose as influencing management control under Article 154 of Korea's Capital Markets Act. This is the Korean equivalent of a 13D filing with a management-control purpose, signaling that the group is actively consolidating control through ongoing accumulation following a 75% share-count reduction.

Star Cheer Corporation Limited and related parties increased their stake in CQV Co., Ltd. (101240.KQ) to 50.73% from 49.84% through open-market purchases of 100,621 shares at prices between KRW 3,630 and KRW 3,707. The group spent KRW 371 million in cash on the additional shares, which are held across Star Cheer, Global New Material International Holdings Ltd (10.56%), and registered executive Jung Sung-ki (0.12%). The filing declares a "management influence" holding purpose citing nine permitted activist grounds under Article 154 of the Capital Markets Act, including director appointment and charter changes. Star Cheer is a Hong Kong intermediate holding company ultimately controlled by Global New Material International Holdings Ltd with SU Ertian serving as the common representative. This Korean large shareholding report with a management-control purpose is the local equivalent of a US 13D activist filing and signals the group may now push for active operational influence, board changes, or M&A after crossing the 50% ownership threshold without triggering a mandatory tender offer.

CEO Moon Young-woo and six special affiliates of GRITEE, Inc. (204020.KQ) filed a large shareholding report declaring a management-control purpose under Article 147 of the Capital Markets Act. The group increased its combined stake to 42.44% from 41.23% through on-market purchases between May 26 and May 29. Affiliate Son Moon Myung-ki acquired 208,267 shares using KRW 474M borrowed from a related party under a 10-year loan term. The group explicitly asserts influence over board composition, charter amendments, capital changes, and M&A activity. This Korean management-control filing is the local equivalent of a US 13D with an activist agenda, formally clearing the CEO-led group to push for structural changes or capital restructuring without triggering a mandatory tender at the 50% threshold.

Lee Sang In and a coalition of 107 co-holders filed a large-shareholding disclosure for a 5.74% stake in Daeho Al Co.,Ltd. (069460.KS). The group holds 999,555 shares via a joint-holding agreement and designated the filing for management-control purposes under Korea's Capital Markets Act. Led by a retail shareholder alliance representative, the coalition intends to normalize management and resume trading for the currently suspended KOSPI-listed shares. The group reserves rights to propose director appointments or removals, bylaw changes, and capital actions. This Korean large-shareholding report allows the 5.74% bloc to push for board changes without triggering a mandatory tender offer and clears the 3% threshold required to call an extraordinary shareholder meeting.

T.S. Investment Corporation (246690.KQ) CEO and chairman Kim Wung filed a large shareholding report on June 1, 2026, reclassifying his group’s 32.87% stake for the purpose of influencing management control. The filing marks a shift from passive to active intent under Article 147 of the Capital Markets Act and follows the addition of director Byeon Gi-su as a new special-relationship party. The group, which includes TS Investment Holdings (14.91%) and Kim Wung personally (17.75%), currently holds 15,629,508 shares, down from 34.76% due to dilution from a approximately 6.5% increase in the total share count. While the group reported no immediate plans for specific control actions, it reserves the right to exert influence on management matters in the future. This designation serves as the Korean equivalent of a US 13D filing, clearing the group to push for board changes or capital restructuring with a 32.87% block that sits just above the one-third threshold to block special resolutions under Korean commercial law.

Nam Yun-hee and an alliance of 133 co-filers disclosed a 5.98% stake, or 5,065,345 shares, in Enzychem Lifesciences (183490.KQ) through a June 1, 2026, DART large-shareholding report. The group primary designated the filing under the 'management-control purpose' category, the Korean equivalent of a US 13D, to signal intent to influence board composition and corporate policy. Declared activist objectives include influencing board and auditor appointments or dismissals, bylaw amendments, and capital changes to normalize management and restore trading in the company's currently suspended KOSDAQ shares. This filing is a rare escalation for a suspended biotech that clears the group to pursue shareholder proposals and litigation to force trading resumption and governance overhaul.

Seoryong Electronics Co., Ltd. and 17 related parties reported a 66.11% stake in Sungho Electronics Corp. (043260.KQ) as of May 29, 2026, designating a "management influence" purpose. This filing reserves the right to pursue board changes, capital restructuring, dividends, and M&A, supported by a January 2026 shareholder agreement governing board composition and disposal restrictions. Currently, 56.9% of the company's total shares are pledged as collateral for loans exceeding KRW 400 billion, with additional convertible and warrant bonds carrying asset sale call rights exercisable after December 8, 2026. This Korean filing is the local equivalent of a US 13D with control intent, allowing the group to pursue board changes or a take-private without triggering a mandatory tender offer, though the pledged stake at vehicles with negative equity introduces structural margin-call risk.

Blue Industrial Development Co., Ltd. (006740.KS) disclosed a large shareholding report from PMA Association and related parties reporting a 33.63% stake following a 12:1 capital reduction on May 8, 2026. The group’s voting rights are restricted to 23.38% due to pledged shares, though economic ownership includes 733,627 shares held via convertible bonds. The filing specifies a purpose of influencing management, listing board composition changes, capital structure decisions, and M&A as intended actions. Special related party has 403,710 shares pledged as collateral for a KRW 1.5B loan from Orient-Western maturing June 11, 2026. This Korean large shareholding report with management-control purpose is the local equivalent of a US 13D, and the 23.38% voting power versus 33.63% economic ownership gap creates a concentrated control vector while the June 11 loan maturity adds near-term forced-sale risk.

Daon International disclosed a 14.9% stake in Seoul Electronics & Telecom (027040.KQ), becoming the largest shareholder following the off-market acquisition of 2,073,196 shares on May 21, 2026. The position was established at an average price of KRW 1,864 per share using KRW 3.87B in borrowings from Kratos Inc. and Song Jin-young. Under the 'management control' purpose filing, Daon International expressed intent to influence director appointments, bylaw changes, capital structure, and M&A strategy. This large shareholding report is the Korean equivalent of a 13D, although the entire 14.9% stake is pledged as collateral for acquisition loans, creating a structural overhang if the share price weakens relative to the 160% collateral maintenance ratio.

Green ESG Growth No.1 PEF disclosed a 34.02% stake in Optrontec Inc. (082210.KQ), an increase from its previous 12.22% holding. On May 27, the fund acquired KRW 25B of convertible bonds and sold common shares, causing its common stock voting rights to fall from 4.88% to 4.21%. The report was filed with a management-influence purpose under Korean Capital Markets Act Article 147. Ultimate control of the fund traces to Woori Financial Group, which owns 100% of the GP, Woori Private Equity Asset Management. This filing is the Korean equivalent of a US 13D activist filing, clearing the filer to push for board changes and corporate restructuring while the acquisition of deeply in-the-money convertible bonds concentrates economic exposure ahead of a potential control squeeze.

STIC Litmus LLC reported an 18.38% stake in LabGenomics (084650.KQ) following the KRW 20 billion acquisition of convertible bonds on May 20, 2026. The 13,642,564-share position was established at a conversion price of KRW 1,466 per share using self-funded capital. STIC Litmus is an investment vehicle managed by STIC Investments Inc., a Korean private equity firm with over KRW 305B in total assets. The May 28 DART disclosure cites a management control influence purpose under Article 147 of the Capital Markets Act. This large shareholding report is the local equivalent of a US 13D, clearing the filer to push for board changes or capital restructuring as the entry via convertible bonds at a deep discount signals a structured activist play.

Nam Yun-hui and an alliance of 124 minority shareholders filed a large shareholding report disclosing a combined 5.95% stake in ENZYCHEM Lifesciences (183490.KQ). The group utilized the 'general' format under Article 147 of the Capital Markets Act with the explicit purpose of influencing management control. Stated intentions include exercising shareholder rights concerning director appointments and removals, auditor actions, bylaw changes, capital restructuring, and M&A proposals. The reporting obligation for the 5,035,780-share position arose on May 26, 2026, representing a new bloc formation with no disclosed interests in derivatives or convertible instruments. This control-purpose declaration is the Korean equivalent of a coordinated US 13D filing and clears the 124-person grassroots alliance to seek board seats or agitate for a sale without triggering a mandatory tender offer.

PMA Association filed a large-shareholding report disclosing a 23.38% stake in Blue Industry Development Co., Ltd. (006740.KS), shifting its holding purpose to "management control influence" under Article 147 of Korea’s Capital Markets Act. While the group’s 13,320,985-share position is unchanged from its prior report, the formal declaration of intent includes director appointment or removal, bylaw amendments, and potential M&A or restructuring. On May 11, 2026, concert party File Engineering executed a stock collateral loan with Orient-Western covering 4,844,529 shares, or 8.50% of the issuer. The escalation from a passive filing to a statutory declaration of management influence intent signals a potential control contest or board shakeup.

WEHUB Inc. filed a large shareholding report disclosing an intent to influence management control of Focus AI Co., Ltd. (331380.KQ). WEHUB and its related parties hold a 38.80% stake, totaling 12,576,895 shares, which is an increase from 38.50% following stock option grants to an executive. Total voting rights for the group remain at 28.17%, representing 9,131,575 votes. The filing under Article 147 of Korea’s Capital Markets Act marks an escalation from a passive stake disclosure to an activist stance. The shareholder group reserved the right to influence director appointments, bylaw changes, capital structure, dividends, M&A, and dissolution. This declaration signals potential governance changes, board shake-ups, or M&A pressure at the KOSDAQ-listed software development company.

SBW Inc. filed an amended large-shareholding report disclosing a 44.73% stake in Vivien Corp. (002070.KS) with the intent to influence management. SBW increased its position from 17.3% through the conversion of Vivien’s 3rd series convertible bonds on April 24, 2026, and a subsequent 1-for-26.4 capital reduction. Now holding 1,075,542 shares, SBW explicitly reserved the right to influence board composition, capital structure changes, M&A, and asset disposals under Article 154 of the Korea Capital Markets Act. The filing, dated May 20, 2026, corrects a prior April 27 report that misstated the post-reduction share count. This capital-reduction restructuring concentrated control into a 44.73% voting block, signaling a potential de facto control change at the South Korean apparel manufacturer.

Neospes LLC filed an initial large-shareholding report disclosing a 6.12% stake in KOSDAQ-listed Dreamus Company (060570.KQ). The 4,531,522-share position arose from the termination of a prior joint-holding agreement, converting existing holdings into a standalone reportable block. Neospes is wholly owned by NeoFlux No. 3 Private Equity Partnership and managed by Shinhan Venture Investment. The May 11, 2026, filing defines the holding purpose as "influence management control" and "board participation." The disclosure of explicit control intent creates a near-term catalyst for board engagement or potential proxy activity.

Align Partners Asset Management increased its activist stake in Coway (021240.KS) from 5.07% (3,590,395 shares) to 5.30% (3,750,764 shares) as of April 17, 2026, via open market purchases and block trades, while also reducing shares under key contracts from 3.94% to 2.82% and releasing pledged shares. Stake acquired through open market purchases and off-hours block trades; no aggregate purchase price disclosed. Coway total voting shares outstanding: 70,767,426. Align Partners is a known Korean activist with a multi-year engagement thesis at Coway, and the continued open-market accumulation — combined with the reduction in pledged and contractually encumbered shares — suggests the firm is consolidating clean, unencumbered voting power ahead of further engagement. The reduction in shares subject to key contracts narrows Align Partners' contractual leverage, and Coway's management has not publicly indicated responsiveness to prior shareholder proposals.

Doronicum Co., Ltd. has completed a second public tender offer for Douzone Bizon, acquiring 1,213,466 common shares at ₩120,000 per share, with settlement occurring today; the offer fell short of its target of 2,965,604 shares, as only 1,213,466 shares were tendered. Offer price: ₩120,000 per share (cash); target quantity was 2,965,604 shares; actual shares acquired: 1,213,466; tender period ran March 27 – April 22, 2026, with settlement April 24, 2026. Following this second tender and a prior block purchase from founding shareholders completed March 26, 2026, Doronicum now holds 86.5% of common shares and 94.0% of total shares excluding treasury stock, placing it above the threshold typically required to initiate a squeeze-out of remaining minority holders under Korean capital markets law. The tender attracted only ~41% of the targeted shares, leaving a meaningful minority float; if Doronicum pursues a compulsory acquisition, minority holders may contest the ₩120,000 price through appraisal proceedings.

Telcon RF Pharmaceutical (텔콘알에프제약) filed a large shareholding report on South Korea's DART disclosing that its stake in KPM Tech has increased to 32.68% of voting shares, up from 14.77% previously, following a share consolidation and acquisition of new shares through a paid-in capital increase — making it the largest shareholder. Telcon RF Pharmaceutical now holds 8,076,935 shares representing 32.68% of KPM Tech's 24,709,362 voting shares; the obligation to report arose on April 18, 2026. Terms of the paid-in capital increase (price per share, total proceeds) are not disclosed in the filing. The filing is classified under the "purpose of influencing management control" provision of Korea's Capital Markets Act (Article 147), meaning Telcon RF Pharmaceutical has formally declared control-oriented intent — giving it legal standing to push for board representation or strategic changes at KPM Tech. Telcon RF Pharmaceutical's own largest shareholder is KPM Tech's subsidiary NewOn (뉴온), which holds 64% of Telcon RF Pharmaceutical — creating a circular ownership structure that complicates governance outcomes and limits the practical independence of the activist position.

Hankook & Company, the controlling shareholder of Korea Tire & Technology, filed a large shareholding change report on April 24, 2026 disclosing that a special related party deposited additional shares (신규 유가증권 공탁), increasing the group's shares subject to major contracts from 5,895,919 (4.76%) to 7,095,919 (5.73%), while the core direct stake held by Hankook & Company remains unchanged at 53,501,364 shares (43.19%). No transaction price or consideration disclosed; the change reflects a deposit of 1,200,000 additional shares into a major-contract position by a special related party, lifting that tranche from 4.76% to 5.73% of total voting shares. The filing was submitted under the "purpose of influencing management control" track of Korea's Capital Markets Act (Article 147), meaning Hankook & Company has formally declared a control-oriented intent — the incremental share deposit by a related party tightens the controlling group's aggregate grip ahead of any potential boardroom or governance contest. The filing discloses no new activist demand, board proposal, or opposing shareholder; without a visible opposing force or stated demand, this is a control-tightening filing rather than an active campaign.

Align Partners Capital Management filed a large shareholding report with Korea's DART disclosing an increase in its stake in Solum (KRX: 248070) from 23.02% to 23.11% (50,000 additional shares), with the filing purpose classified as influencing management — the highest-intent category under Korean capital markets law. Align Partners increased its holding by 50,000 shares, bringing the total position to 12,666,959 shares (23.11% of 54,816,236 voting shares); the shares subject to pledge/collateral arrangements now stand at 11,190,752 shares (20.42%). The obligation date was April 17, 2026. Align Partners, a known Korean activist manager led by Lee Chang-hwan, has consistently been buying and is now above 23% — a level that materially complicates any capital allocation or governance decision by incumbent management and raises the cost of ignoring shareholder demands. The filing's immediate trigger is a pledge/collateral arrangement on the incremental shares, not a fresh open-market purchase, limiting the read-through as a pure conviction add; the large pledged position (20.42%) introduces overhang risk if financing conditions change.

Small shareholders of Hanwha Solutions have organized through the ACT platform to oppose the company's ₩2.4 trillion rights offering, accumulating 2.87% of shares and appointing attorney Chon Gyeong-deuk as their representative. ₩2.4 trillion rights offering with ₩1.5 trillion designated for debt repayment. Parent company Hanwha Corporation plans to invest approximately ₩700 billion to maintain its 36.31% stake. Minority shareholders approaching the 3% threshold required under Korean Commercial Code to call extraordinary meetings and exercise enhanced voting rights, potentially forcing board representation or strategic review of the controversial debt refinancing structure. Parent company support for the rights offering and regulatory approval from Korea's Financial Supervisory Service could override minority opposition. Monitor for crossing 3% ownership threshold enabling extraordinary meeting requisition rights under Korean Commercial Code.

Activist fund Align Partners Capital Management sent a second open letter pressuring for governance reforms and enhanced shareholder returns, including adopting return-based management strategy and strengthening payout policies. The fund also questioned the $1.65 billion Fortegra acquisition given the company’s cautious stance on shareholder payouts, prompting DB Insurance to announce cancellation of 5.6% of treasury shares.

Taekwang announced a strengthened shareholder return plan targeting 45%+ annual returns for 2027-2029, up from the previous 30% target for 2024-2026. The company will also execute 10 billion won in share buybacks following direct negotiations with U.S. hedge fund Dalton Investment, which acquired a stake last year.

Korean Corporate Governance Forum is supporting activist fund Palliser Capital’s shareholder proposals demanding all 7 proposals be included in the AGM agenda. The proposals include restricting controlling shareholder LG Corp’s voting rights on conflicted matters, restructuring the board with business experts, establishing an independent NAV discount reduction committee, and selling non-core assets including a 2% stake in Korea Zinc worth 651 billion won.

British investment manager Palliser Capital disclosed a 1%+ stake in SK Square and pushed for value unlocking through expanded investments and larger share buybacks. SK Square’s stock surged over sevenfold from 78,000 won to 560,000 won, with further gains to 679,000 won as US hedge fund Third Point also targets the company for valuation enhancement.

Align Partners Capital Management has submitted shareholder proposals for the 26th Annual General Meeting targeting governance improvements and capital allocation discipline. The company trades at 6.6x LTM EV/EBITDA and 0.77x P/B versus global peer averages of 14.0x and 3.13x respectively.

Activist fund TRUSTON Asset Management (1.87% stake) sent a public shareholder letter demanding liquidation of Samsung C&T holdings and improved shareholder returns. KCC’s Samsung C&T stake is valued at 4.9 trillion won, exceeding KCC’s market cap of 4.1 trillion won, creating a 55% NAV discount.

Align Partners Capital Management has submitted formal shareholder proposals for Coway’s 37th AGM and published their third public shareholder letter. The activist is targeting Coway’s undervaluation, with shares down 16% from 2019 levels despite strong business growth. Align Partners is demanding board response by March 13, 2026.

UK activist Palliser Capital reduced its stake from 1.01% to 0.67% but continues targeting structural undervaluation. LG Chem announced plans to reduce LG Energy Solution holdings to 70% over 5 years from current 79.4%. Palliser’s demands include board improvements, better capital allocation, share buybacks using LG Energy stakes, and discount management programs.

Major shareholder Youngpoong-MBK Partners has submitted shareholder proposals at the 52nd annual meeting including director fiduciary duty bylaws, 10-for-1 stock split, executive officer system, and electing 6 directors through cumulative voting including MBK nominees. The proposals aim to normalize the company’s governance structure.

The board has decided to oppose shareholder proposals from Strategic Capital and other investors. The company formally resolved to recommend shareholders vote against the activist proposals.

GL Pharm Tech Corp. (204840.KQ) filed a statutory merger disclosure on KOSDAQ on May 28, 2026, followed by an amended merger agreement filed on June 1, 2026. This filing, designated as 주요사항보고서(회사합병결정), is the Korean equivalent of a US Form 8-K announcing a signed definitive agreement. The amended agreement signals near-final terms, with the arb spread contingent on forthcoming specifics regarding the merger ratio, surviving entity, and shareholder meeting date.

Logen Co., Ltd. (033290.KQ) is set to absorb its affiliate Modainochip Co., Ltd. in a stock-for-stock merger at a ratio of 1 Logen share for every 0.9755740 Modainochip share. The transaction involves the issuance of 76,394,770 new Logen shares based on merger prices of KRW 2,047 for Logen and KRW 1,997 for Modainochip. DaeMyung Chemical Co., Ltd. is the controlling shareholder of both entities, holding 48.78% of Logen and 75.25% of Modainochip. The merger agreement includes a walk-away trigger if combined appraisal-rights buyback obligations exceed KRW 10 billion. A June 4, 2026, corrective disclosure adjusted the appraisal-rights payment dates to October 29, 2026, for Modainochip and November 6, 2026, for Logen. The June 19, 2026, record date is the first hard deadline for minority shareholders to exploit the ~3.4% spread between the Logen merger price and the KRW 2,116 statutory appraisal floor.

Moda-InnoChips Co., Ltd. (080420.KQ) will be absorbed by Rosen Inc. in a subsidiary merger involving entities controlled by Dae Myung Chemical Co., Ltd. The transaction features a merger ratio of 1 Rosen share for every 0.9755740 Moda-InnoChips shares, with a statutory appraisal price of KRW 2,005 per share for dissenting shareholders. Dae Myung Chemical holds 75.25% of Moda-InnoChips, and the deal is subject to a shareholder vote scheduled for September 18, 2026, requiring approval from two-thirds of votes cast and one-third of total issued shares. An amendment filed June 4, 2026, accelerated the appraisal payment date for Moda-InnoChips shareholders to October 29, 2026. The KRW 2,005 appraisal price functions as a floor return for minority shareholders, and the revised payment schedule improves the implied IRR by shortening the window between exercise and settlement.

Huons (243070.KQ) is proceeding with a statutory merger to absorb its R&D subsidiary, Huons Lab Co., Ltd. The merger ratio is set at 1 Huons share for every 0.4256943 Huons Lab shares, requiring the issuance of 3,825,373 new shares. Huons Lab, which has a pending domestic drug approval, reported negative equity of KRW -1.8B and a net loss of KRW -10.2B for FY2025. A June 4 correction to the merger report delayed the shareholder record date to July 30, 2026, with the shareholder meeting now scheduled for August 21 and an expected close on September 23. This related-party absorption of a distressed subsidiary entails 24.2% dilution and may trigger appraisal rights, with the statutory buyback price of 32,886 KRW representing a 5.9% discount to the 34,062 KRW implied merger value.

EM-Tech (091120.KQ), a KOSDAQ-listed manufacturer of electronic components including micro-speakers, antennas, and vibration motors for mobile and automotive applications, filed amended board opinion letters on May 26 and May 27, 2026. These filings update an initial May 22 major-event report regarding a statutory merger decision under the Korean Commercial Code. The transaction requires shareholder approval to proceed. These procedural amendments indicate ongoing progress toward a shareholder vote. The amendment cycle suggests terms are being finalized; the next catalyst is the shareholder meeting date and merger ratio disclosure, which will set the arb spread for this KOSDAQ-listed name.

Solux (290690.KQ) is absorbing unlisted biotechnology firm Aribio Co., Ltd. in a reverse merger that will result in the surviving entity adopting the Aribio name and headquarters. The fixed merger ratio is one Solux share for every 2.0610695 Aribio shares, with Solux expected to issue 52,737,384 new common shares. Following its 28th amended merger report, Solux reset the shareholder meeting to August 25, 2026, and pushed the expected closing date to September 29, 2026. An appraisal-rights exercise period will run from August 25 through September 14, 2026, at a buyback price of KRW 10,719. The merger can be terminated if appraisal-rights claims exceed KRW 1.5 billion at Solux or KRW 3.0 billion at Aribio. The transaction functions as a reverse-merger "SPAC-lite" for the Alzheimer's-drug developer, with the updated schedule providing new timeline anchors for arbitrage positioning around the KRW 10,719 appraisal-rights floor.

Huons (243070.KQ) filed a second corrective DART disclosure to amend the merger ratio and delay the timeline for its absorption of unlisted subsidiary Huonslab Co., Ltd. by approximately five weeks. The corrected merger ratio is 1 Huons share for every 0.4256943 Huonslab common shares, following the pre-close conversion of 905,420 Huonslab preference shares. Advisor Ichon Accounting Corp. valued Huons at KRW 34,062 per share and Huonslab at KRW 12,671–14,672 per share, with the latter valuation supported by a 16-year revenue plan despite a KRW 808 per share asset value. Shareholders will vote August 21, 2026, preceding a September 23 record date and an October 12 listing, though the board may terminate the deal if appraisal-rights buybacks exceed KRW 30 billion for Huons or KRW 4 billion for Huonslab. The transaction involves 24.2% dilution through the issuance of 3.8 million new shares and provides an arbitrage window until late August to evaluate the KRW 34,062 parent valuation against market price.

Huons (243070.KQ) entered a definitive agreement on May 18, 2026, to absorb its unlisted biotech affiliate, Huonslab, in a statutory merger scheduled for registration on August 18, 2026. The transaction uses a merger ratio of 1 Huons share to 0.4256893 Huonslab shares, requiring the issuance of 3,825,327 new common shares and resulting in 24.2% dilution. While Huonslab brings a hyaluronidase-based drug platform and biopharma R&D pipeline, the affiliate reported a KRW 10.2B net loss in 2025 and negative equity of KRW 1.8B. Ichon Accounting Corp provided an external valuation setting the Huons appraisal value at KRW 34,062 and the Huonslab appraisal range between KRW 12,671 and KRW 14,672. A shareholder meeting for the vote is scheduled for July 16, 2026, for shareholders of record as of June 16, with dissenter rights set at KRW 32,886. New shares are expected to list on September 4, 2026.

NowCos (257990.KS) is scheduled to delist from the KONEX market on June 1, 2026, following a share exchange squeeze-out by Asterion Holdings Co., Ltd. Asterion Holdings became the 100% parent after acquiring the remaining minority shares for KRW 8,300 per share in cash, representing total consideration of approximately KRW 1.3B. The share exchange agreement was signed on March 17, 2026, and became effective on May 18, 2026, following shareholder approval on April 15, 2026. Five minority shareholders exercised appraisal rights for 3,451 shares at KRW 8,300, resulting in a total payout of KRW 28.6 million. On May 14, 2026, NowCos cancelled 3,471 treasury shares, including those obtained through the appraisal exercise.

Asiana Airlines (020560.KS) will be absorbed by its 63.88% majority shareholder Korean Air Lines Co., Ltd. in a statutory short-form merger. Minority shareholders will receive 0.2736432 new Korean Air shares per Asiana share, with the merger expected to close on December 16, 2026, and new shares listing on January 4, 2027. The Asiana board resolution on May 13, 2026, initiates the consolidation of Korea’s two full-service carriers and eliminates the dual-listed structure. A shareholder meeting is scheduled for August 12, 2026, following the merger agreement signing on May 14, 2026. Appraisal rights trigger if aggregate dissent payments exceed KRW 1 trillion, with Asiana's buyback price set at KRW 7,030 per share. Post-merger, Hanjin Kal's stake in Korean Air will dilute from 26.13% to 24.76% with no change in control.

Majority shareholders of Gonggu Women (366030.KQ) entered into a definitive agreement to sell a 44.14% stake to CCG Monument Holdings for KRW 72 billion. Kim Joo-young and TS 2018-12 M&A Investment Association are selling a combined 10 million shares at KRW 7,200 per share. According to a May 13 amended large-shareholding report, the closing date for the transaction was extended from May 12 to May 19, 2026. The sellers will retain 4.82 million shares and were granted a put option at KRW 4,774 per share. The block trade transfers control of the KOSDAQ-listed company.

Korean Air (003490.KS) board resolved on May 13, 2026, to absorb its 63.88%-owned subsidiary Asiana Airlines via a small-scale merger under Article 527-3 of the Korean Commercial Code. The transaction utilizes a ratio of 0.2736432 Korean Air shares for each Asiana share, implying a valuation of approximately KRW 6,953 per share and involving the issuance of 20,337,721 common shares. This simplified structure bypasses a Korean Air shareholder vote unless 20% or more of shares object in writing within two weeks. Korean Air will assume Asiana’s debt of approximately KRW 11.4T, with the merger expected to be effective on December 16, 2026, subject to overseas antitrust and Ministry of Land approvals. New Korean Air shares are scheduled to list on January 4, 2027. The absorption marks the final integration phase to simplify the control structure and resolve dual-listing inefficiencies.

교보15호스팩 (465320.KQ) filed a third amendment to its merger report on May 11, 2026, postponing its absorption merger with OLED materials and equipment firm CMDL Co., Ltd. The shareholder meeting is now scheduled for July 23, 2026, with the merger closing on August 28, 2026, and listing set for September 15, 2026. Under the ratio of 1 Kyobo 15 share for 0.1515793 CMDL shares, CMDL will survive the transaction to achieve a KOSDAQ listing. CMDL’s largest shareholder, Now IB 14 Fund, holds a 73.04% stake that is expected to reach 76.73% post-merger assuming convertible bond conversion. Shinhan Accounting Corp. is the advisor for the deal. The postponement impacts arbitrage positioning around voting, redemption rights, and listing-date reference pricing.

Logen Co., Ltd. (033290.KQ) filed a correction report on May 11, 2026, delaying the scheduled absorption merger of fellow Daemyung Chemical subsidiary Moadainnochip Co., Ltd. by approximately four months. The share exchange ratio is set at 1 Logen share for 0.9755740 Moadainnochip shares, with Logen issuing 76,394,770 new common shares at an offering price of KRW 2,047 per share. The shareholder vote is now scheduled for September 18, 2026, and the merger is expected to close on November 2, 2026. Shareholders of record as of June 19, 2026, will have appraisal rights at a buyback price of KRW 2,116 per share. Daemyung Chemical Co., Ltd. is the controlling shareholder of both entities, holding 48.78% of Logen and 75.25% of Moadainnochip.

Mirae Asset Vision SPAC No. 7 (482680.KQ) signed a definitive merger agreement on May 12, 2026, to acquire unlisted used-car retailer Auto Hands Co., Ltd. via a KOSDAQ de-SPAC absorption merger. The transaction utilizes a merger ratio of 1 Auto Hands share for 0.2509636 SPAC shares, reflecting an implied per-share value for Auto Hands of KRW 7,969 and a SPAC offer price of KRW 2,000 per share. Post-merger, Auto Hands' largest shareholder, Kang Gui-ho, will hold approximately 52.51%, or 49.21% on a fully diluted basis including convertible bonds. The deal is advised by Jeongdong Accounting Firm and is contingent on a shareholder vote scheduled for October 7, 2026. The merger is expected to become effective on November 11, 2026, with the listing of new shares on November 26, 2026.

엔에이치스팩29호 (451700.KQ) filed a third amendment to its merger report, signaling imminent closing of its absorption by unlisted special-purpose machinery manufacturer Semitis Co., Ltd. The amended schedule establishes a trading suspension from May 18 to June 9, 2026, with new shares scheduled to list on June 10, 2026. Under the terms of the agreement signed November 14, 2025, the merger ratio is 1 Semitis share for 0.4432624 엔에이치스팩29호 shares. Shareholder approval was obtained April 17, 2026, and the CEO of Semitis is expected to hold a 52.94% post-merger stake. Semitis reported FY2024 revenue of KRW 19.2B and net income of KRW 5.3B. Ichon Accounting Firm is serving as advisor for the transaction.

Synopex Inc. (025320.KQ) filed a corrective amendment to its subsidiary merger agreement on May 13, 2026. The filing follows an initial major-event report for the merger decision submitted on April 23, 2026, and a prior amendment on April 24, 2026. Documents attached to the corrective filing include revised merger contract and plan terms. The filing signals potentially revised exchange ratios, conditions, or structures for the South Korean subsidiary merger.

Wysiwyg Studios (299900.KQ) filed an amended merger report for its intra-group combination with NP Inc., rescheduling the shareholder meeting to June 12, 2026, and the merger record date to July 14, 2026. The transaction was accelerated to avoid new KOSDAQ delisting criteria effective July 1, 2026, following correction requests from the Financial Supervisory Service. Surviving entity NP Inc. will cancel 9.14 million treasury shares received from Wysiwyg and initiate a 5:1 post-merger share consolidation. Largest shareholder Com2uS, which currently holds 38.05% of Wysiwyg Studios, is expected to own approximately 28.30% of the combined entity. Hanmi Accounting Corporation and LAB Partners Law Firm are advising on the transaction, with the former providing fairness validation for NP Inc. shareholders. The revised timetable and appraisal rights periods present tactical event-driven dynamics ahead of the revised 2026 deadlines.

Woori Financial Group is absorbing Tongyang Life Insurance as a wholly owned subsidiary via a share exchange, with all minority shareholders of Tongyang Life to receive Woori Financial Group shares in exchange for their Tongyang Life shares. Exchange ratio: 0.2521056 Woori Financial Group shares per 1 Tongyang Life share, derived from volume-weighted average prices with exchange values set at KRW 34,589 for Woori Financial Group and KRW 8,720 for Tongyang Life; no discount or premium was applied to the statutory averages. This is a compulsory squeeze-out structure — Woori Financial Group, already the parent of Tongyang Life, is eliminating the minority float entirely, meaning remaining public shareholders receive a fixed exchange ratio into the parent with no cash alternative disclosed. Minority shareholders who oppose the exchange have appraisal rights under Korean capital markets law, and any legal challenge to the exchange ratio could delay delisting; the ratio is based purely on market price averages with no independent valuation premium. Share exchange agreement signing is scheduled for April 29, 2026.

Woori Financial Group is executing a small-scale share exchange to absorb Tongyang Life Insurance Co., Ltd. as a wholly owned subsidiary, with Tongyang Life minority shareholders receiving Woori Financial shares in exchange for their Tongyang Life shares. Exchange ratio is 0.2521056 Woori Financial shares per one Tongyang Life share, derived from volume-weighted average prices as of April 23, 2026: Woori Financial exchange price KRW 34,589 (~USD 25), Tongyang Life exchange price KRW 8,720 (~USD 6.30); no cash consideration; share exchange agreement to be executed April 29, 2026. Tongyang Life minority shareholders receive Woori Financial stock at a fixed ratio with no discount or premium applied, making the spread between Tongyang Life's market price and the implied exchange value the primary arbitrage variable ahead of the exchange effective date. As a small-scale share exchange under Korean capital markets law, Woori Financial does not require a shareholder vote, limiting minority shareholder recourse; dissenting Tongyang Life shareholders may exercise appraisal rights, but the exchange can proceed regardless. Share exchange agreement signing on April 29, 2026; monitor DART for the formal exchange effective date filing and any appraisal rights exercise disclosures.

E-MART Inc. is conducting a stock exchange transaction with Shinsegae Food Inc. to become the complete parent company through a share swap arrangement. Exchange ratio 1:0.5031313 (E-MART:Shinsegae Food), with Shinsegae Food shareholders receiving 0.5031313 shares of E-MART treasury stock for each Shinsegae Food share held. Related-party consolidation eliminates minority interests in the food subsidiary while creating potential arbitrage around the exchange ratio calculation based on Korean market regulations. Shareholder meeting scheduled for April 30, 2026 (rescheduled from April 16).

엔젠바이오 filed a merger completion report with Korea’s DART system. Terms undisclosed. Korean biotech merger completion suggests consolidation in the sector, with potential for operational synergies and cost reduction driving value creation. Monitor for detailed merger terms and combined entity strategy disclosure.

케일럼 completed a merger transaction according to DART filing 합병등종료보고서(합병). Terms undisclosed. Korean regulatory filing indicates completed merger structure, though specific strategic rationale and counterparty details require further disclosure review. Monitor for additional DART filings with merger details and business combination specifics.

모바일어플라이언스 filed a material event correction report with DART regarding a decision to sell convertible bonds with share buyback rights. Terms undisclosed. Korean company’s convertible bond sale decision suggests potential capital restructuring or liquidity needs requiring regulatory disclosure correction. Monitor for detailed terms disclosure in follow-up DART filings.

휴먼테크놀로지 filed a material event report with Korea’s DART system regarding a merger decision. Terms undisclosed. Korean regulatory filing indicates formal merger approval, creating potential arbitrage opportunity pending disclosure of counterparty and exchange ratio. Monitor for detailed merger terms disclosure in follow-up DART filings.

NH SPAC 29 filed a corrected material event report regarding a merger decision with Korea’s DART system. Terms undisclosed. Korean SPAC merger decisions typically involve target identification and shareholder approval processes that create definitive transaction timelines. Monitor for detailed merger terms and target company disclosure in subsequent DART filings.

Hanwha Solutions (009830.KS) reduced its planned rights offering to KRW 1.71T ($1.14B) from KRW 2.4T following two rejections by South Korea's Financial Supervisory Service. Management will issue 53,000,000 new shares at KRW 32,250 per share, lowering potential dilution to approximately 30% from the originally proposed 42%. To cover a KRW 100B funding gap, the board authorized the sale of U.S. venture fund stakes as a direct concession to shareholder protests. The revised allocation directs KRW 801.5B toward debt repayment and KRW 907.7B to perovskite tandem cell and TOPCon production expansion. Existing shareholder subscription is scheduled for July 22-23, with new shares expected to list on August 11. With final terms established after significant regulatory and investor pushback, the focus shifts to whether the reduced dilution and fund-sale concessions are enough to stabilize the stock into the July subscription window.

Hanwha Solutions (009830.KS) resumed its KRW 1.8 trillion rights offering on May 14 following a two-day suspension driven by FSS revision requests. The offering of 56,000,000 common shares follows a size reduction from an initial KRW 2.4 trillion plan and is scheduled for a June 5 record date with subscription from July 10 to July 16. Gross proceeds are allocated as 907.7 billion won for facility investment and 906.7 billion won for debt repayment. Major shareholder Hanwha plans to subscribe for its full allocation plus up to 20% oversubscription. The 50% debt-repayment allocation has drawn investor concern alongside broader dilution risks and recent regulatory pushback.

Hanwha Solutions (009830.KS) is proceeding with a KRW 1.81 trillion ($1.22B) rights offering of 56,000,000 common shares after the Financial Supervisory Service (FSS) demanded disclosure corrections regarding liquidity risks and alternative financing. The offering price is currently set at KRW 32,400 per share, with the final price to be determined July 7, 2026, and shareholder subscriptions scheduled for July 10 to 13. Gross proceeds are allocated as KRW 907.7 billion for facility investments and KRW 906.7 billion for debt repayment. Parent company Hanwha Corp. will participate in the capital increase, and new shares are expected to begin trading on July 31, 2026. The FSS’s scrutiny represents an ongoing regulatory overhang that could impact the offering’s timeline, pricing, or terms.

The offering was reduced on April 17 from approximately KRW 2.4 trillion to KRW 1.8 trillion, with funds earmarked for debt repayment cut from KRW 1.5 trillion to approximately KRW 900 billion; the offering represents roughly 30% of the company's market capitalization. Two FSS revision requests in under four weeks signal that disclosure deficiencies remain unresolved, keeping the offering in regulatory limbo and extending share price overhang; the bull case hinges on a scaled-back, growth-focused deal clearing approval and triggering a re-rating once dilution risk is priced. A third revision cycle or outright abandonment of the offering remains possible, and any further reduction in deal size or additional delay prolongs.

Lunit secured a $21 million anchor commitment from Atinum Investment for its ongoing $140 million rights offering, with Atinum acquiring 960,000 shares including 85% of subscription rights from the chairman and CEO. Rights offering targets $140 million at a 21% discount to market price, with Atinum committing $21 million and management reinvesting proceeds from their rights sales back into the offering. Institutional anchor reduces execution risk for dilutive financing while management reinvestment signals confidence, plus planned 1-for-1 bonus issue provides additional shareholder value post-closing.

Hanwha Solutions scaled back its rights offering from ₩2.4 trillion to ₩1.8 trillion ($1.2 billion) following regulatory scrutiny from Korea's Financial Supervisory Service. The company will issue 56 million new shares at ₩32,400 per share (down from 72 million shares at ₩33,300), with a rights ratio of 0.2604 new shares per existing share and subscription deadline May 14. The scaled-back offering addresses regulatory concerns and shareholder criticism while still providing ₩906.7 billion for debt reduction, potentially reducing dilution impact by 22% compared to the original plan. The offering still creates substantial dilution for existing shareholders, and the company reduced debt repayment allocation by ₩583 billion while maintaining facility investment spending unchanged.

Clobot announced a rights offering to issue 5.49 million common shares at 36,400 won per share, raising approximately 200 billion won through shareholder allotment with forfeited shares offered to the general public. Issue price 36,400 won per share for 5,494,500 new shares, raising ~200 billion won. Proceeds allocated: 37.6 billion won for operating expenses, 162.3 billion won for acquiring other companies' securities. The stock dropped 17% to 42,700 won on announcement, trading at a 15% premium to the 36,400 won issue price, creating potential value opportunity if the discount to trading price persists and management's acquisition strategy delivers synergies. Rights offering dilutes existing shareholders by 22%, and 81% of proceeds will fund unspecified acquisitions rather than core autonomous driving operations. Monitor for rights offering record date and subscription period details.

Lunit announced a rights offering to raise up to ₩250 billion ($165 million), with preliminary proceeds now estimated at ₩211.5 billion ($140 million) following shareholder approval at the annual meeting. Rights offering proceeds estimated at ₩211.5 billion ($140 million) with final pricing on April 17, 2026. Maximum offering size ₩250 billion ($165 million). The offering removes ₩197 billion ($130 million) put option risk from convertible bonds used to acquire Volpara Health, eliminating forced redemption pressure from short-duration bondholders and moving the company toward break-even. Shareholders expressed concerns about dilution and limited management participation in the offering, with convertible bond overhang creating additional equity valuation complexity. Final rights offering price set April 17, 2026.

Clobot is preparing to complete a rights offering of 5.49 million common shares representing 22% of outstanding shares. Rights offering priced at ₩36,400 per share, a 29.3% discount to the ₩51,500 closing price. Total proceeds ₩200 billion. Rights offering at steep discount creates arbitrage opportunity as shares trade above offering price, with downward pressure likely as dilution approaches. Monitor for rights offering completion date and subscription results.

Union Korea Pharm Co., Ltd. (080720.KQ) announced that Bukwang Pharmaceutical Co., Ltd. acquired a 75.14% controlling stake for KRW 30 billion via a third-party allotment capital increase. The transaction was executed on May 28, 2026, and involved the issuance of 60,000,000 newly issued common shares at KRW 500 per share under a court-approved rehabilitation plan. Bukwang Pharmaceutical, whose ultimate parent is OCI Holdings Co., Ltd., funded the acquisition through self-raised capital and existing company reserves. The newly issued shares are subject to a mandatory six-month lock-up agreement with the Korea Exchange, preventing disposal until the listing date of the shares. This court-supervised recapitalization exit creates an illiquid overhang on 75% of shares outstanding, but Korea United Pharm remains under rehabilitation court supervision, which limits near-term corporate action until the court terminates proceedings.

Tong Yang Life Insurance (Dongyang Life) executed a comprehensive share exchange agreement with its parent, Woori Financial Group, on April 29, 2026, under which all minority shareholders of Dongyang Life will transfer their shares to Woori Financial Group in exchange for newly issued Woori Financial Group shares. Exchange ratio: 0.2521056 Woori Financial Group shares per one Dongyang Life share; the ratio was calculated using a statutory formula averaging the volume-weighted closing prices over the most recent one month, one week, and the most recent trading day, with no discount or premium applied. A cash offer price was not disclosed — consideration is entirely in Woori Financial Group shares. The arb trade is purely a spread between the implied per-share value of Dongyang Life (0.2521056 × Woori Financial Group share price) and where Dongyang Life currently trades; with a signed definitive agreement and a fixed exchange ratio, the remaining variable is Woori Financial Group's share price between now and closing. A decline in Woori Financial Group's share price directly compresses the implied offer value with no floor, and Korean Financial Services Commission or exchange regulatory approval delays extend exposure to that price risk.

BCPE EABD Co. One (a private acquirer) is executing a cash-for-share exchange to absorb EcoMarketing as a wholly owned subsidiary, following a series of three public tender offers that brought its ownership to near-100%, with the share exchange designed to squeeze out remaining minority shareholders and voluntarily delist the company. The exchange consideration is KRW 16,000 per share in cash — identical to the preceding tender offer prices — representing a 49.5% premium to EcoMarketing's closing price on December 30, 2025 (KRW 10,700) and a 36% premium to the prior three-month volume-weighted average price of KRW 11,763. Minority shareholders who did not tender in any of the three prior offers will be cashed out at KRW 16,000 per share through the compulsory share exchange; the special committee, advised by Samjong KPMG, concluded the price exceeds valuations derived from DCF and comparable transaction analyses, limiting the case for dissent appraisal. Shareholders who believe intrinsic value exceeds KRW 16,000 have limited recourse, as the special committee has already opined the price is fair and the acquirer holds dominant control, leaving appraisal rights as the primary — and uncertain — avenue for redress.

Xtwin No. 1 Partnership (엑스트윈스1호조합), the largest shareholder of B2N (307870.KQ), reduced its stake from 24.48% (18,190,436 shares) to 21.26% (15,800,854 shares) as of April 17, 2026, following partial settlement of a share transfer agreement and an amendment agreement among the reporting entity and related parties. The reduction represents a disposal of approximately 2,389,582 shares; no transaction price was disclosed in the filing. The controlling bloc is actively unwinding its position via a structured share transfer — with contracted shares (주요계약체결) also declining from 16.86% to 13.65% — indicating further scheduled disposals remain in the pipeline beyond this tranche. Xtwin retains 21.26% with additional shares still subject to transfer contracts at 13.65%, meaning ongoing supply overhang from the largest shareholder is not resolved by this filing.

Osung Advanced Materials, the largest shareholder of RF-Tech (061040.KQ), filed a large shareholding report on April 22, 2026 disclosing a combined stake increase from 33.65% (13,780,457 shares) to 39.95% (18,072,302 shares), driven by the addition of Nadia New Technology Association No. 68 — a tech venture investment fund managed by Eastgate Investment — as a newly designated special related party. The stake increase of approximately 6.3 percentage points reflects the consolidation of 4,291,845 additional shares under the reporting group; no transaction price or cash consideration is disclosed. With combined voting rights now at 39.95% of RF-Tech's 45,241,115 issued shares, Osung Advanced Materials is approaching a threshold that meaningfully constrains minority resistance to corporate actions, and the stated purpose — influence over management rights — puts further strategic moves clearly on the table. No specific action plan has been disclosed, leaving the market to speculate on timing and form of any follow-on move; the fund vehicle at the center of the increase (Nadia No. 68) is 99.99%-funded by a single investor, introducing concentration risk in the related-party structure.

S-FORM Co., Ltd. launched a partial tender offer to acquire 1,200,000 shares of Sammok S-FORM (018310.KQ) at KRW 22,800 per share, totaling KRW 27.36B. The tender period for the 8.16% stake runs from May 18 to June 8, 2026, with settlement on June 10. NH Investment & Securities is acting as the tender offer agent. S-FORM Co., Ltd. currently holds a 38.80% stake, and the acquisition will increase the aggregate ownership of S-FORM and special related parties from 69.47% to 77.63%. The offer is intended to stabilize management control and increase decision-making efficiency, explicitly not for delisting or M&A purposes. Sammok S-FORM manufactures and leases aluminum and specialty forms used in construction and is listed on the KOSDAQ.

TKG Taekwang (티케이지태광) completed its tender offer for TKG Aikang Co., Ltd., purchasing 11,101,047 shares at ₩900 per share, raising its total stake from 47.53% to 68.96% of shares outstanding. Offer price: ₩900 per share (cash); 11,101,047 shares tendered and settled on April 29, 2026 against a maximum of 27,177,088 shares sought; the offer ran March 31 – April 24, 2026. TKG Taekwang now controls 68.96% — above the 50% control threshold but well below the ~95% Korean squeeze-out threshold — leaving minority shareholders exposed to a potential follow-on tender or mandatory delisting process if the acquirer elects to take the company fully private. TKG Taekwang has not indicated any intention to launch a second offer, and at 68.96% it may elect to hold at this level indefinitely, leaving remaining minority holders with no near-term liquidity event.

티케이지태광 filed tender offer documentation for 티케이지애강 with South Korea’s DART system. Terms undisclosed. Korean tender offers often involve parent companies consolidating subsidiary holdings or strategic buyers acquiring control positions at regulated pricing. Monitor for tender offer commencement announcement with specific pricing and acceptance period.

Doronicum filed tender offer results with DART for Douzone Bizon shares. Terms of the completed tender offer have not been disclosed in the available filing summary. The acquisition of Korea’s leading ERP software provider represents consolidation in the domestic enterprise software market. Monitor for detailed tender offer results disclosure in the complete DART filing.

Former Daou Kiwoom Chairman Kim Ik-rae will launch a tender offer for 900,000 shares of Saramin. Terms including offer price, premium to market, and tender period have not been disclosed. The tender offer provides a potential liquidity event for shareholders of the Korean recruitment platform, though the absence of pricing details limits immediate assessment of value. Monitor for formal tender offer documents disclosing price and timeline.

Douzone Bizon (012510.KS) filed a corrected material-fact report detailing disclosures on director fiduciary duties and fairness measures for its take-private by Doronicum Co., Ltd. Remaining minority shareholders will be cashed out via a stock exchange at KRW 120,000 per share, a 25% premium to the last close before the initial tender offer. Doronicum Co., Ltd. and Doronicum Singapore, LP currently hold 96.92% of shares following two successful tender offers. The stock exchange agreement was approved by the board on April 27, 2026, following a recommendation from an independent special committee of outside directors. Financial advisor Samil PwC and legal advisor Lin Law Firm provided fairness opinions confirming the exchange price is within or above the estimated fair value range. The transaction will result in the delisting of the enterprise software company from the Korea Exchange.

Douzone Bizon (012510.KS) will be acquired by Doronicum Co., Ltd. in a comprehensive share exchange at KRW 120,000 per share in cash. The enterprise IT and software company filed a corrective disclosure on May 11, 2026, amending appraisal-rights procedures for the going-private transaction, which represents a 0.76% premium. Structured as a small-scale exchange under the Korean Commercial Act, the deal proceeds via board resolution and does not require a shareholder meeting. Douzone Bizon shares are expected to delist from the KOSPI market on July 15, 2026, with Hanul Accounting Corp. serving as advisor. The appraisal-rights exercise period runs from May 28 to June 17, 2026, following a May 12 record date for dissent. Transaction closing is scheduled for June 30, 2026.

Finger Inc. (163730.KQ) founder Park Min-soo has transferred control to Seoryong Electronics Co., Ltd. through a shareholder agreement and the OTC sale of 2,390,959 shares to Seoryong and other investors. Seoryong Electronics acquired a 10.12% stake and gained the right to appoint two of three board directors and the auditor, with the total reported stake at 32.83%. Park reported a 0% stake after transferring shares and ceding representative reporter status. A put option allows Park to sell his remaining shares to Seoryong Electronics starting two years after the May 4, 2026 agreement date. This change-of-control transaction with board capture and a put option effectively takes the company private.

동양생명 (082640.KS) filed a corrective disclosure on May 14, 2026, updating the comprehensive share exchange agreement with its 75.34% owner, Woori Financial Group Inc. Minority shareholders will receive 0.2521056 Woori common shares per Tongyang Life share, resulting in the issuance of 8,696,875 new Woori shares and the subsequent delisting of the insurer from the KRX KOSPI. Significant termination risk was removed after only 0.6% of Woori shares opposed the transaction during the dissenting shareholder period ending May 13, well below the 20% threshold. The US registration strategy has shifted from Form F-4 to Form-CB under a Rule 802 exemption as US ownership represents less than 10% of the minority float. Following the acquisition, Tongyang Life plans to merge with ABL Life Insurance to eliminate intra-group inefficiencies. The transaction is expected to close on August 11, 2026, with the next catalyst scheduled for July 24, 2026.

12 (477760.KQ) and K Solution Co., Ltd. mutually terminated their February 12, 2026 merger agreement after the target withdrew its preliminary listing review application with the Korea Exchange. The merger, which would have given K Solution's largest shareholder Hong Jin-ki a 51.63% stake in the combined entity, was formally cancelled via a May 26, 2026 corrective DART disclosure. All subsequent deal milestones, including the shareholder meeting, share buyback rights, and the listing of new shares, are now cancelled. The SPAC must identify a new merger target within its remaining life or face liquidation and trust redemption. This termination returns 477760.KQ to a blank-check search phase where the trust redemption floor serves as the arb floor until a new target announcement or extension-vote filing.

Careena Transportation Group, an investment vehicle controlled by Affinity Asia Pacific Fund V L.P., terminated its share purchase agreement to acquire a 56.17% stake in Lotte Rental (089860.KS) from Hotel Lotte and Busan Lotte Hotel. The transaction, originally signed on March 11, 2025, involved 20,396,594 shares and was reported as terminated effective May 18, 2026, according to a May 26 DART filing. The collapse of the 56.17% control block sale removes a take-private or control-change catalyst that had been pending since March 2025. The seller group now holds the block again and may seek a new buyer, restarting the control-premium optionality for Lotte Rental's remaining float.

교보16호스팩 (482520.KQ) filed a corrective report announcing the mutual termination of its merger agreement with SK Pack after SK Pack withdrew its KRX preliminary listing review due to internal circumstances. Consequently, all scheduled merger-related events, including shareholder meetings and share purchase rights, have been cancelled. The transaction was originally structured with a ratio of 1 SK Pack share for 0.2119991 교보16호스팩 shares, with SK Pack intended as the surviving entity and Leejung Accounting Firm serving as an advisor. This termination eliminates the de-SPAC catalyst for 교보16호스팩, leaving the company to identify a new target or proceed toward trust-value liquidation within its remaining term. SK Pack manufactures automated liquid filling and packaging machinery for general industrial use.

Yuhan Corp (000100.KS) announced plans at its Seoul R&D Day on May 28, 2026, to spin off its allergy treatment candidate, YH35324, into a separate NewCo. The proposal is part of a "post-Lazertinib" strategy to capture standalone value for the allergy pipeline while the parent retains existing oncology drug royalties. No official timetable or valuation for the transaction has been announced as of May 29, 2026. The key variables to watch for this pure-play biotech separation are the capital structure and ownership split at the NewCo, which have not yet been disclosed.

Hanwha Corporation (000880.KS) filed an amended report on May 14, 2026, for the human spin-off of its machinery, services, and holdings segment into a new entity tentatively named Hanwha Machinery & Service Holdings. The spin-off ratio was revised to 0.7563533 for the surviving entity versus 0.2436467 for the new entity following treasury share cancellations. All key milestone dates were delayed by one month, with the shareholder meeting now scheduled for July 15, 2026, and the split date set for August 1, 2026. The new entity is expected to be re-listed on the KOSPI on August 25, 2026. This corporate split aims to streamline defense and energy businesses from machinery and services, creating a pure-play opportunity and a potential index rebalancing event.

Hanwha Solutions (009830.KS) filed an amended corporate split decision report (회사분할결정) with Korea's DART on April 21, 2026 — the second amendment to an original filing dated January 14, 2026, with a prior amendment filed March 11, 2026. The DART filing index does not disclose spinco identity, valuation, exchange ratio, or expected completion date. Three rounds of filings over three months suggest the split structure remains in active negotiation. Korean corporate splits historically create re-rating opportunities as holding-company discounts compress around the separated entity.

T’way Air’s largest shareholder Sono International will fully subscribe to its allocated 26.85 million shares in the airline’s rights offering. The company plans to use proceeds for fleet expansion with A330-900NEO aircraft and long-haul route expansion to Europe, North America and Australia.

Hana Financial Group is preparing to announce additional ‘value-up’ initiatives beyond its already committed 400 billion won treasury share cancellation in H1 2026. The company is proposing to reduce capital reserves by 7.4 trillion won to transfer to retained earnings for future dividends, with shareholder return ratio reaching 47%.

South Korea is implementing new disclosure requirements forcing publicly traded companies with PBR below 1.0 for over two years to disclose corporate value enhancement plans. Samsung Electronics is specifically mentioned as needing to present a detailed value-up plan after its shareholders’ meeting, with regulators criticizing simplified disclosures for high dividend companies.

SeAH Holdings (058650.KS) launched a self-tender offer to acquire up to 187,000 common shares, representing 4.41% of its outstanding stock, at KRW 160,000 per share. The total maximum consideration is KRW 29.92 billion, and the company intends to cancel all acquired shares to enhance shareholder value. The tender period is scheduled from May 20 to June 8, 2026, with a settlement date of June 10, 2026. NH Investment & Securities is acting as the tender offer agent. The controlling shareholder and related parties currently hold 76.1% of the shares outstanding. As of December 31, 2025, the company's treasury stock acquisition limit was KRW 782.2 billion.

Shinhan Financial (SHG) announced its 'Value-Up +++' plan in a May 16, 2026, 6-K filing alongside Q1 2026 net profit of W 1.65T. The enhanced shareholder return policy targets a total shareholder payout ratio of 50%+ and utilizes buybacks for capital distribution. The plan also establishes financial targets for a 10-12% ROE and a CET1 ratio of at least 13%. These measures align the South Korean financial holding company with ongoing government-led 'Value-Up' corporate reforms.

Bain Capital is conducting its third tender offer at 16,000 won per share to delist Ecomarketing, running March 3 through March 31, 2026, after securing ~91% through two prior rounds but falling short of the 95% threshold required for voluntary delisting.

Private equity firm EQT is conducting a tender offer to acquire all remaining shares at 120,000 won per share, following its 37.6% control stake acquisition in November 2024. The tender offer runs until March 24, 2026, with EQT planning to delist the company.

케이지에이 (455180.KQ) completed the KRW 10,500,000,000 sale of land and buildings in Hwaseong-si, Gyeonggi-do, to Able Tech Co., Ltd. The transaction, advised by Donghyun Accounting Corporation, closed on May 15, 2026, following the receipt of final payment and completion of ownership transfer registration. Post-transfer, total assets for the company decreased by approximately KRW 3.49 billion, while total liabilities were reduced by KRW 4.09 billion. The sale price excludes VAT and incidental costs. This divestiture represents a capital recycling event to improve the balance sheet and potentially sharpen strategic focus.

Douzone Bizon's board has approved a tender offer as part of a voluntary delisting process from the Korea Exchange. The delisting process eliminates public trading complexity for Korea's leading ERP software provider while providing exit liquidity for remaining public shareholders. Minority shareholders face forced exit if delisting threshold is met, with limited recourse if they view the offer price as inadequate.

SK Hynix confidentially filed Form F-1 for a U.S. dual listing while maintaining its KOSPI listing. Company targets $10-14 billion capital raise through 2% dilution in second half 2026. Clean AGM passage removes execution risk for the memory chip giant’s U.S. dual listing, potentially narrowing the valuation discount to American semiconductor peers despite SK Hynix’s dominant position in AI-critical high-bandwidth memory. U.S. listing expected second half 2026. Previously : Confidentially filed Form F-1 targeting $10-14 billion capital raise through 2% dilution in second half 2026.

Poongsan is reviewing structural reforms including potential sale of its profitable munitions business for ~$1 billion to resolve succession issues, as chairman’s son holds U.S. citizenship which restricts him from managing Korean defense firms. Company has hired Lazard, Kim & Chang, and Samil PwC as advisers, though maintains no final decision made.

SKC announced a 1 trillion won ($750M+) rights offering to fund 590 billion won investment in glass substrate subsidiary Absolics and 410 billion won debt repayment. Major shareholder SK will oversubscribe at 120% of allocation, reducing debt ratio from ~230% to low-140% range.